ID | Year | Stage | Disease course (years) | Male/ Female | Age (EG/CG) | Intervention(s) of the EG | Intervention(s) of the CG | Details of ①/ ② | Outcomes | Duration (days) | Number of subjects (EG/CG) | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
EB + ① vs. ① | ||||||||||||
Pan | 2010 | I | EG:1.50 ± 1.20 CG:1.70 ± 0.80 | EG:14/10 CG:13/11 | 62.10 ± 5.80 | 61.40 ± 7.10 | EB + ① | ① | Thiazide diuretics, Gastrodia and Uncaria Decoction | SBP, DBP, GLU, TG, TC, HDL-C, Insulin | 168 | 24/24 |
Chen | 2012 | I, II | EG:10 ± 8 CG:11 ± 7 | EG:25/15 CG:23/17 | 59 ± 6 | 60 ± 5 | EB + ① | ① | Nifedipine extended-release tablets 10-20 mg/time, 2times/d | SBP, DBP, Serum hs-CRP | 168 | 40/40 |
Chen | 2013 | I | EG:9.13 ± 3.69 CG:8.30 ± 4.36 | EG:13/14 CG:16/12 | 70.06 ± 3.51 | 69.23 ± 3.72 | EB + ① | ① | Anneizhen 5 mg or Norvasc 5 mg or Telmisartan 80 mg, 1 time/d | SBP, DBP, Serum NO, Plasma ET-1 | 84 | 30/30 |
Liao | 2013 | I, II | EG:4.80 ± 2.10 CG:3.90 ± 3.10 | EG:38/32 CG:36/34 | 60.50 ± 11.80 | 62.70 ± 9.50 | EB + ① | ① | Walking 40 min + Amlodipine 5 mg, 1 time/d | SBP, DBP, FBG, TC, TG, BMI, HbA1c, Waist, Insulin | 180 | 70/70 |
Liang | 2014 | I, II | EG:4.30 ± 3.00 CG:4.70 ± 3.20 | EG:20/10 CG:18/12 | 54.80 ± 7.60 | 55.70 ± 8.80 | EB + ① | ① | NR | SDP, DBP, TC, TG, HDL-C, LDL-C | 180 | 30/30 |
Yang | 2014 | I, II | NR | EG:19/16 CG:13/22 | 60.07 ± 5.84 | 60.60 ± 7.37 | EB + ① | ① | NR | SBP, DBP, SF-36, Heart Rate, Respiration | 168 | 35/35 |
He | 2015 | I | EG:8.23 ± 3.73 CG:8.51 ± 3.42 | EG:22/20 CG:23/19 | 68.51 ± 2.97 | 69.24 ± 2.45 | EB + ① | ① | NR | SBP, DBP | 90 | 42/42 |
Chen | 2016 | I | EG:8.12 ± 3.53 CG:8.61 ± 3.32 | EG:15/13 CG:14/14 | 69.98 ± 3.31 | 70.29 ± 1.77 | EB + ① | ① | NR | SBP, DBP | 84 | 28/28 |
Liang | 2016 | Isolated systolic hypertension | EG:9.3 ± 2.6 CG:11.9 ± 5.8 | EG:17/13 CG:16/14 | 68.1 ± 10.1 | 70.5 ± 10.2 | EB + ① | ① | Amlodipine 5 mg, 1 time/d (add Valsartan 80 mg, 1time/d, when necessary) | SBP, DBP, Self-made quality of life scale | 90 | 30/30 |
Lin | 2017 | I | NR | 62/54 | 58 ± 7.48 | EB + ① | ① | Amlodipine 5 mg or Telmisartan 80 mg, 1time/d | SBP, DBP, Heart Rate, NO, ET-1 | 180 | 58/58 | |
EB + ②. vs. ② | ||||||||||||
Dong | 2016 | I | 0.42 ± 0.08 | 34/26 | 51.40 ± 4.20 | EB + ② | ② | Routine health education | DBP, SBP | 60 | 30/30 | |
Yu | 2013 | I | NR | NR | NR | NR | EB + ② | ② | Intensive education per 2 months during the treatment period | SBP, DBP, BMI, WHR | 360 | 52/52 |
Shi | 2017 | I | EG:2.55 ± 1.36 CG:2.67 ± 1.25 | EG:19/11 CG1:18/12 | 42.65 ± 9.85 | 41.58 ± 9.12 | EB + ② | ② | Low-salt and low-fat diet education | SBP, DBP | 180 | 30/30 |
Li | 2019 | I | EG ≤ 5,23>5,6CG: ≤5,20;>5,7 | EG:6/23 CG:6/21 | 57.41 ± 3.38 | 55.81 ± 4.09 | EB + ② | ② | Diet education | FBG, SBP, DBP, HbA1C | 360 | 30/30 |